Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Poland

Research and Innovation Action · Running

HIT-GLIO Targeting tumour-host interactions in paediatric malignant gliomas to reinvigorate immunity and improve radio- and immunotherapy efficacy

Coordinator
Instytut Biologii Doswiadczalnej Im. M. Nenckiego Polskiej Akademii Nauk, Poland
Runs
1 December 2023 to 30 November 2027
Status
Running
EU funding
€9.7m
Total cost
€9.7m
Partners
11 organisations in 8 countries
Type
Research and Innovation Action
Grant agreement
101136835

What the project is doing

In the project's own words, from its summary on CORDIS.

Paediatric high-grade gliomas (pHGGs) are malignant, deadly tumours developing in infants and children. Mutations in histone coding genes disturb epigenetic regulation and in cooperation with other oncogenes promote tumour initiation and progression. pHGGs are fast-growing and diffusive which makes them hard to remove or treat. Surgery (unattainable in midline brain regions) and radiotherapy (RT) remain the only option with transient benefits as median survival is 9-15 months.

Those tumours are immunosuppressed, thus immunotherapy is ineffective. We propose that knowledge of tumour-host interactions in the tumour microenvironment (TME) would reveal novel targets allowing to find new ways to eradicate mutated tumour cells, improve efficacy of RT, and reinvigorate anti-tumour immunity. To achieve these ambitious goals we built up the international, multidisciplinary consortium HIT-GLIO. We will i) use latest single-cell technologies and multimodal imaging to characterise tumour-immune cell interactions in a large spectrum of pHGG patient samples; ii) create cellular and animal models of increasing complexity: human glioma-microglia co-cultures, DIPG-derived organoids complemented with iPSC-derived immune cells and syngeneic pHGG mouse models which would be platforms for mechanistic studies and drug screening; iii) evaluate hypoxia-inducible epigenetic inhibitors and blockers of tumour-host interactions to improve RT and immunotherapy responses; iv) generate nanocarriers functionalised to target immune cells and deliver drugs to the brain; v) develop more effective CAR-T cells that together with TME reprogramming and RT would boost anti-tumour immunity; vi) assess neurodevelopmental alterations and psychological consequences of disease and foster psychological approaches to increase quality-of-life of patients and caregivers.

The expected outcomes of HIT-GLIO would ultimately pave ways to new clinical trials to improve the way pHGGs are treated. This action is part of the Cancer Mission cluster of projects on “Understanding (tumour-host interactions).

Topics

Who is involved

OrganisationCityCountryRole
Instytut Biologii Doswiadczalnej Im. M. Nenckiego Polskiej Akademii NaukWarszawaPolandCoordinator
Royal Institution for the Advancement of Learning Mcgill UniversityMontrealCanadaAssociatedpartner
The Research Institute of the Mcgill University Health CentreMontrealCanadaAssociatedpartner
Genexplain GmbHWolfenbuttelGermanyParticipant
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Institut Gustave RoussyVillejuifFranceParticipant
Tel Aviv UniversityTel AvivIsraelParticipant
Istituto Superiore Di SanitaRomaItalyParticipant
Stichting Sanquin BloedvoorzieningAmsterdamNetherlandsParticipant
Instytut Pomnik Centrum Zdrowia DzieckaWarszawaPolandParticipant
The Chancellor, Masters and Scholars of the University of OxfordOxfordUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI